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Abstract
Current limitations of chemotherapy include toxicity on healthy tissues and multidrug resistance of malignant cells. A
number of recent anti-cancer strategies aim at targeting the mitochondrial apoptotic machinery to induce tumor cell death.
In this study, we set up protocols to purify functional mitochondria from various human cell lines to analyze the effect of
peptidic and xenobiotic compounds described to harbour either Bcl-2 inhibition properties or toxic effects related to
mitochondria. Mitochondrial inner and outer membrane permeabilization were systematically investigated in cancer cell
mitochondria versus non-cancerous mitochondria. The truncated (t-) Bid protein, synthetic BH3 peptides from Bim and Bak,
and the small molecule ABT-737 induced a tumor-specific and OMP-restricted mitochondrio-toxicity, while compounds like
HA-14.1, YC-137, Chelerythrine, Gossypol, TW-37 or EM20-25 did not. We found that ABT-737 can induce the Bax-dependent
release of apoptotic proteins (cytochrome c, Smac/Diablo and Omi/HtrA2 but not AIF) from various but not all cancer cell
mitochondria. Furthermore, ABT-737 addition to isolated cancer cell mitochondria induced oligomerization of Bax and/or
Bak monomers already inserted in the mitochondrial membrane. Finally immunoprecipatations indicated that ABT-737
induces Bax, Bak and Bim desequestration from Bcl-2 and Bcl-xL but not from Mcl-1L. This study investigates for the first
time the mechanism of action of ABT-737 as a single agent on isolated cancer cell mitochondria. Hence, this method based
on MOMP (mitochondrial outer membrane permeabilization) is an interesting screening tool, tailored for identifying Bcl-2
antagonists with selective toxicity profile against cancer cell mitochondria but devoid of toxicity against healthy
mitochondria.
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Introduction
Apoptosis dysregulation has been shown to underly several
pathologies including cancer [1,2]. It is well established that
diverse signalling events within apoptosis converge on mitochon-
dria which undergo outer membrane permeabilization (OMP)
triggering the release of soluble apoptogenic factors from the
intermembrane space such as cytochrome c and a subsequent
series of activation of a set of proteolytic enzymes, the caspases
conducting to apoptotic dismantling of cell structure [3].
MOMP is under the control of members of the Bcl-2 protein
family which includes (1) anti-apoptotic proteins like Bcl-2, Bcl-xL,
Bcl-w, Mcl-1 and A1/Bfl-1 containing all four Bcl-2 homology
domains (BH1-4), (2) pro-apoptotic proteins like Bax, Bak, Bok
lacking the BH4 domain and (3) pro-apoptotic BH3-only proteins
like Bid, Bim, Bad, Bmf, Noxa and Puma [4–8]. In the direct
activation model, induction of Bim or Bid is required for Bax or
Bak to oligomerize and form pores in the outer mitochondrial
membrane (MOM) [9,10]. The anti-apoptotic proteins can block
this process at the MOM by primarily sequestering Bax/Bak
proteins [11–13]. In the indirect activation model [14,15], BH3-
only proteins can antagonize anti-apoptotic effect and liberate
Bax/Bak proteins. It is still a matter of debate whether Bax and
Bak may interact with proteins like VDAC (voltage dependent
anion channel) and/or ANT (adenine nucleotide translocator) to
regulate the permeability transition pore (PTP) [16]. At the
mitochondrial level, the cytochrome c is distributed in two distinct
pools: 15–20% in the intermembrane space and the larger fraction
(80%) in the intracristae space [17]. Thus, BH3 mimetic peptide
needs matrix remodeling to release the second pool of cytochrome
c [18]. Other apoptotic factors like Omi/HtrA2 and Smac/
DIABLO (caspase-dependent death effectors) or the apoptosis-
inducing factor AIF and EndoG (caspase-independent death
effectors) are released after MOMP.
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is often altered in cancer cells possibly as a result of PTP
component overexpression [19], upregulation of anti-apoptotic
members of the Bcl-2 family and/or downregulation of Bax [20].
These underly numerous anti-cancer strategies targeting compo-
nents of the core cell death machinery to promote tumor cell death
[21,22]. These strategies are based on the use of BH3-mimicking
peptides [14,23], antisense [24] or RNA interference [25] against
Bcl-2, and natural or synthetic small molecules which bind
specifically to Bcl-2 family proteins. For instance screening
approaches using nuclear magnetic resonance, structure-based
design and combinatory chemical synthesis, led to the identifica-
tion of ABT-737, a small-molecule inhibitor of the anti-apoptotic
proteins Bcl-2, Bcl-xL and Bcl-w but not Mcl-1 and A1/Bfl1 [26].
ABT-737 is considered to be a Bad-like BH3 mimetic because
both ABT-737 and Bad BH3 peptide bind the same subset of Bcl-2
pro-survival proteins [27] and induce cytochrome c release in
mitochondria obtained from ‘‘primed for death’’ tumor cells [28].
However, the weak affinity of ABT-737 for the pro-survival
proteins Mcl-1 and A1/Bfl1 [26] might be a key determinant of
tumor cell resistance to this compound [29].
We have set up a multiparametric screen on purified mitochon-
dria to identify compounds inducing OMP of mitochondria isolated
from cancer cell lines, but not of mitochondria isolated from non-
cancerous cells. Among various compounds (from chemical,
peptidic or proteic origins) described to target mitochondria, we
found that only recombinant t-Bid, Bak BH3 and Bim BH3
peptides, and ABT-737 present a direct tumor-specific mitochon-
drio-toxicity and induce relatively large OMP due to Bax and Bak
oligomerization. By further exploration of ABT-737-induced OMP
at the cell-free mitochondrial level, we found that (1) cancer cell
mitochondria from different sources differed in their sensitivity to
ABT-737 correlating with different patterns of (outer) membrane-
associated Bcl-2 family members and their interactions, (2) ABT-
737 induces Bax, Bak, and Bim desequestration from Bcl-xL and
Bcl-2, but not from Bcl-w or Mcl-1.
Results
Isolation and functional characterization of healthy and
tumor mitochondria
Mitochondria from both healthy tissue (mouse liver) and human
tumor (PC-3, prostate) cell line were purified by isopycnic
centrifugation in density gradients of Percoll. The isolated
mitochondria were found highly intact as demonstrated by
cytochrome c oxidase accessibility assay and flow cytometry
FSC/SSC analysis [30]. Ultrastructural comparative studies of
isolated mitochondria from liver or PC-3 tumor cell line reveal a
relatively similar matrix/cristae organization despite a slight
difference in density between tumor (low density) and liver (high
density) mitochondria (Fig. 1A). Calcium (50 mM) induces an
extensive outer membrane disruption in both healthy tissue and
tumor cell line mitochondria followed by a swelling which is
inhibited by cyclosporine A (CsA), indicating an intact and
functional permeability transition pore in both mitochondrial
types. Polarographic investigations were next carried out on liver
and PC-3 mitochondria (Fig. 1B). Succinate oxidation was
essentially dependent on ADP addition and a respiratory control
index (RCI) of 3 associated with succinate oxidation indicated the
functional integrity of mitochondria, including those isolated from
tumor cultured cells. Similarly, mitochondria isolated from HT-
29, HCT-116 and Jurkat cancer cell lines and HME-1 non-
cancerous cell line presented high level of integrity and
functionality (not shown).
Multiparametric screening method on isolated healthy
and tumor mitochondria
Isolated mitochondria were analyzed on a screening platform
which allowed the quantification of the mitochondrial membrane
permeabilization (swelling; Fig. 1C; left panel) plus mitochondrial
transmembrane potential (DYm; Fig. 1C, middle panel) using real-
time spectrofluorimetry and cytochrome c release by ELISA as an
index for MOMP (Fig. 1C; right panel). Real-time DYm detection
reflected inner membrane and respiratory chain alterations but did
not permit to observe delayed DYm in response to pro-apoptotic
compounds. When incubated in hypotonic buffers, both normal
and tumoral cell mitochondria did swell (loss of O.D. at 550 nm)
in the presence of calcium in a CsA-dependent manner. However,
the swelling amplitude was reduced in the case of tumor
mitochondria in agreement with their lowest density compared
to liver mitochondria. Calcium and mClCCP induced a rapid
DYm loss characterized by an increased fluorescence correspond-
ing to Rhodamine-123 dequenching due to a decrease of the dye’s
concentration in depolarized mitochondria. We thus observed that
the recombinant protein t-Bid had no effect on swelling and DYm
but induced cytochrome c release specifically in PC-3 (Fig. 1C),
HT-29, HCT-116 and Jurkat (not shown) cell mitochondria in a
concentration-dependent manner as indicated by ELISA analysis
of the supernatants.
Screening of putative Bcl-2 family inhibitors
We next evaluated the effect of Bcl-2 inhibitors on mitochondria
isolated from mouse liver, human non-cancerous (HME-1) and
cancerous (PC-3) cells using 3 parameters: swelling, DYm and
cytochrome c release (Fig. 2A). The recombinant t-Bid protein
induced cytochrome c release (without swelling and DYm loss)
from PC-3 mitochondria but had no effect on liver and HME-1
mitochondria at 100 nM. Some BH3 peptides (derived from Bak,
Bim, Bax, Bad, Bid, Noxa and Puma) from human or mouse
sources were also tested. Among these, only human Bak BH3 and
Bim BH3 (Fig. 2A) induced mitochondrio-toxicity to tumor cell
(PC-3) mitochondria, while being inactive at 100 mM on liver and
HME-1 mitochondria. Noteworthy, even the corresponding
mouse BH3 sequences are inactive on mouse liver mitochondria,
excluding a misinterpretation due to species specificity (not
shown). In contrast to the other small-molecule inhibitors
evaluated in this study, only ABT-737 displayed tumor mitochon-
dria specificity, inducing cytochrome c release from PC-3
mitochondria but not from liver and HME-1 mitochondria. The
cytochrome c release from PC-3 mitochondria treated with t-Bid
and ABT-737 occured without any swelling (Fig. 2A and
electronic microscopy, not shown) or DYm loss (Fig. 2A) during
a 45 min-treatment, indicating that these conditions occurs a
specific OMP. We then extended the study of ABT-737 effects to
mitochondria isolated from the HCT-116, HT-29 and Jurkat
cancer cell lines (Fig. 2B) and observed different sensitivity to
ABT-737. Indeed, HT-29 mitochondria were much less sensitive
to ABT-737 than PC-3, HCT-116 and Jurkat, these three laters
presenting a similar level of sensitivity to ABT-737. These data
suggested that ABT-737 induces cytochrome c release from
various but not all mitochondria isolated from cancer cells.
ABT-737-induced MOMP in cancer cell mitochondria is
associated with Bak and/or Bak oligomerization
We subsequently investigated if ABT-737-induced OMP was
selective to cytochrome c or might allow the release of other
apoptogenicmitochondrialfactors(Fig.3).Isolated mouseliver,PC-
3 and Jurkat mitochondria were treated with Bak BH3, ABT-737
Cancer Mitochondria Targeting
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DIABLO (23 kDa) and Omi/HtrA2 (37 kDa) were released from
PC-3 and Jurkat mitochondria whereas AIF (56 kDa) was not
(Fig. 3), suggesting that these compounds induced a mitochondria
remodeling not sufficient for AIF release. We next used isolated
mitochondria from the Bax and/or Bak knock-out HCT-116 cell
lines in which absence of Bax and/or Bak was checked by
immunoblot (Fig. 4A). We found that ABT-737 induced cyto-
chrome c release from Bax+/- and Bak-/- mitochondria but not
from Bax-/- or Bax/Bak double knock-out mitochondria (Fig. 4B).
This data pointed out the critical role of Bax in the mechanism of
action of ABT-737. Furthermore, t-Bid and ABT-737-induced
MOMP wascontrolled by an excessof Bcl-xL (Fig. 4C)orBcl-2 (not
shown) recombinant proteins, supporting the hypothesis of a
formation of a specific channel at the outer membrane [31].
Having found that Bax remained bound to the mitochondrial
OM even after a wash with an alkaline homogenization buffer
(pH 11.6) (not shown) suggesting an insertion of Bax into the
membrane [32], we further wanted to examine if ABT-737 might
induce oligomerization of the Bax and Bak pools already
associated to tumor cell mitochondria. Similar to t-Bid and Bim
or Bak BH3 peptides, ABT-737, induced Bax and/or Bak
oligomerization in PC-3 and Jurkat mitochondria, as objectived
using the cross-linking agent 1,6-bismaleimidohexane (BMH;
Fig. 5). Mutated [L78A; D83A] Bak BH3 peptide was inefficient
to induce cytochrome c release and Bax/Bak oligomerization
when added to PC-3 mitochondria (Fig. 5A). In PC-3 mitochon-
dria which contain both Bax and Bak, a weak Bak oligomerization
occured with BH3 peptides or ABT-737 suggesting a major role
for Bax in triggering channels formation in this cell line (Fig. 5A;
middle panels). We next used (6)-1-(3,6-dibromocarbazol-9-yl)-3-
piperazin-1-yl-propan-2-ol identified by Bombrun and co-workers
[33] as a Bax channel blocker (BCB) able to inhibit t-Bid-induced
cytochrome c release [33,34] (Fig. 5A). Pretreatment of cancer cell
mitochondria with this BCB prevented cytochrome c release
triggered by Bak BH3, Bim BH3, t-Bid or ABT-737 treatment
(Fig. 5A). In addition, we found that BCB prevented Bax/Bak
oligomerization in response to treatments with ABT-737, as well as
t-Bid and Bak or Bim BH3 peptides (Fig. 5A and 5B).
Altogether, these data suggested that ABT-737 triggered the
release of apoptogenic proteins from cancer cell mitochondria by
formation of multimeric Bax/Bak channels as shown by
correlation between Bax and Bak oligomerization and cytochrome
c release (Fig. 5).
ABT-737-induced MOMP in cancer cell mitochondria is
associated with particular complex disruptions,
depending on the mitochondrial type
As differences in sensitivity were observed between the several
mitochondrial-types used in this study, we analyzed the pro- and
anti-apoptotic Bcl-2 family members associated to the mitochon-
drial membranes (Fig. 6). Among the anti-apoptotic proteins, Bcl-2
was only present in PC-3, Jurkat and HCT-116 mitochondria,
while Bcl-w, Bcl-xL and A1 were detected in all mitochondrial
types (Fig. 6A). Interestingly, Bcl-xL was quantitatively more
important in cancer cell mitochondria than in their healthy
counterpart. Anti-apoptotic Mcl-1L was present in large quantity
in PC-3 and Jurkat mitochondria and in smaller quantity in HT-
29 mitochondria. Concerning the pro-apoptotic proteins, while
Bak was present in all mitochondrial types, Bax was present in PC-
3, HT-29, HCT-116 and HME-1 mitochondria but not in Jurkat
and liver mitochondria. Among the BH3-only activators, Bim was
found in cancer cell mitochondria but not in those from HME-1
and liver (Fig. 6B) while Bid can not be detected in any of these
mitochondrial types (not shown). Among the BH3 only sensitizers,
Bad was detected at the PC-3, HT-29 and Jurkat mitochondrial
membranes (Fig. 6B), while Puma, Noxa, Hrk, Bik, Bok and Bmf
were not (not shown). Bcl-2, Bcl-xL and BH3 only sensitizers (ex
Bim) might well to be key actors even if it is difficult from such
proteomic analysis to explain the differences in sensitivity to ABT-
737. Indeed it is noteworthy that HME-1 mitochondria have
neither Bim, nor Bcl-2 and only low level of Bcl-xL, which might
distinguish them from sensitive cancer cell mitochondria.
As ABT-737 is acting by complex disruption between pro-
and anti-apoptotic proteins, we next investigated some complex
disruptions by co-immunoprecipitation in PC-3, HT-29 and
Jurkat mitochondria treated with ABT-737 (Fig. 7). Whatever
the cell line we detected similar bindings: Bcl-xL to Bax and Bak,
Bcl-2 to Bax and weakly to Bak, Mcl-1 only to Bak (Fig. 7) and Bcl-
w to Bax (not shown). We observed that ABT-737-induced
cytochrome c release is correlated with Bax, Bak (Fig. 7) and Bim
(not shown) liberation from Bcl-xL and Bcl-2. However, ABT-737
had no effect on Bak and Bim sequestration by Mcl-1 (Fig. 7), or
Bax sequestration by Bcl-w (not shown), these complexes
remaining after treatment. These results suggested that Bax, Bak
and Bim liberation from Bcl-2 and Bcl-xL in response to ABT-737
was responsible for channels formation and cytochrome c release
in PC-3 (Fig. 8) and Jurkat mitochondria. In contrast, HT-29
mitochondria containing less Bim and being deprived of Bcl-2
were less sensitive to ABT-737 treatment, suggesting a major role
for Bcl-2 and Bim in ABT-737 sensitivity.
Discussion
In this study, we used high quality controlled isolated
mitochondria to compare the effects of putative Bcl-2 inhibitors
and try to explore the mechanism of action of ABT-737. We used
five different parameters to evaluate their integrity and functionn-
ality: cytochrome c oxidase accessibility to exogenous cytochrome
c (not shown), respiratory control values, capacity for matrix
swelling, transmembrane potential values and release of apopto-
genic factors like cytochrome c (OMP) (Fig. 1). Comparision of
Figure 1. Isolation and functional characterization of mouse liver and human tumor cell line mitochondria. A. Ultrastructural analysis
of isolated mitochondria and their ability to swell. Electron micrographs were obtained after incubation of mitochondria isolated from healthy mouse
liver, or PC-3 tumor cell lines untreated (NT) or treated with Ca
2+ (50 mM) or with a 5 min-preincubation with cyclosporin A (CsA; 10 mM) or ruthenium
red (RR; 1 mM) before calcium addition. The percentage of swollen mitochondria was ,10% in the control and .80% 30 min after Ca
2+ addition
(n=3). Scale bars 1 mm. B. Oxidative properties of isolated liver and PC-3 mitochondria. Traces represent oxygen consumption by isolated
mitochondria (100 mg) after addition of the indicated reagents. Numbers along the trace are nmoles of O2 consumed per minute per milligram of
protein. The respiratory control index (RCI) is calculated for each type of mitochondria as indicated in Materials and Methods. C. To evaluate
mitochondrial swelling and DYm loss, mitochondria isolated from healthy mice liver or PC-3 cell line were distributed in 96-well microplates and
incubated for 30 min either with Ca
2+ (100 mM) in presence (yellow) or absence (pink) of CsA (10 mM), with mClCCP (turquoise; 50 mM) or with t-Bid
(purple; 1 nM). For quantitation of cytochrome c release, isolated mitochondria were treated with increasing concentrations of the t-Bid recombinant
protein and mitochondrial supernatant was subjected to ELISA assays, given in percentage of release compared to 20 mg/ml alamethicin (Ala; 100%
of cytochrome c release) (n=3 independent experiments).
doi:10.1371/journal.pone.0009924.g001
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high levels of purity and intactness of mitochondrial preparations
whatever their sources (cultured cells or healthy tissue). This was
solved by large-scale cell cultures and purification of mitochondria
by differential centrifugations plus Percoll density gradient. Using
this method, both isolated mouse liver and cancer cell mitochon-
dria present similar quality and response to calcium (Fig. 1).
Surprisingly enough most compounds identified as Bcl-2
inhibitors were found to act on healthy mitochondria at least on
one integrity parameter. For instance, we observed that HA-14.1,
Chelerythrine, Gossypol and EM20-25 induced MMP in mouse
liver mitochondria, while other Bcl-2 family inhibitors were found
to be inactive (YC-137 and TW-37). Appart from t-Bid, Bak BH3,
Bim BH3 which are from proteic origins, only ABT-737
demonstrated selective tumor mitochondrio-targeting indicated
by OMP and release of pro-apoptotic factors (Fig. 2). Previous
observations have proven that ABT-737 can induce OMP either
when mitochondria originate from cells ‘‘primed’’ by death signals
(for instance in IL-3-deprived lymphocytes [28], or in TNF-pulsed
HeLa cells [35]), or when isolated mitochondria are co-treated
with BH3 peptide (for instance with Noxa BH3 on MEF
mitochondria [13]). For the first time, we demonstrated that
ABT-737 can itself induce OMP on mitochondria isolated from
unprimed tumor cell lines. Concerning t-Bid, our isolated liver and
HME-1 healthy mitochondria were not sensitive to the recombi-
nant protein t-Bid. This absence of effect on liver mitochondria
Figure 2. Multiparametric screen of known mitochondria-targeting molecules. A. Mitochondria isolated from mouse liver, human non-
cancerous (HME-1) and cancerous (PC-3) cells were treated with increasing concentrations of t-Bid, Bak BH3, HA-14.1, YC-137, Chelerythrine, Gossypol,
TW-37, EM20-25 and ABT-737 before evaluation of mitochondrial swelling and DYm loss. Alternatively, mitochondrial supernatant was subjected to
ELISA assays for quantification of cytochrome c release. Effective concentration inducing 50% of the maximal effect (EC50) is given for swelling (100%
of effect with 50 mMC a
2+), DYm loss (100% of effect with 50 mM mClCCP) and cytochrome c release (100% of effect with 20 mg/ml alamethicin) (n=3
independent experiments). B. Mitochondria isolated from mouse liver or HME-1, PC-3, HCT-116, HT-29 and Jurkat cell lines were incubated for 45 min
at 30uC with increasing concentrations of ABT-737 and the supernatants were subjected to cytochrome c immunoblot (NT: untreated; Ala:
alamethicin 20 mg/ml).
doi:10.1371/journal.pone.0009924.g002
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mitochondrial preparations. Bcl-2 family proteins detected on both
normal and cancer cells mitochondria (Fig. 6) remind present after
alcaline washes (not shown) indicating that they are not associated
by electrostatic interaction with the mitochondrial membranes and
are not coming from residual cytosol or endoplasmic reticulum.
Figure 3. ABT-737 induces relatively large MOMP in cancer cell mitochondria. Isolated mitochondria from mouse liver, PC-3 and Jurkat cells
were untreated (NT) or incubated either with alamethicin (Ala; 20 mg/ml; positive control), Bak BH3 peptide (10 mM), ABT-737 (1 mM) or recombinant
t-Bid (1 nM) for 45 min. Mitochondrial supernatants were subjected to immunodetection of cytochrome c, Smac/DIABLO, Omi/Htra2 and AIF
(Western blots are representative of 3 independent experiments). Note that cytochrome c (15 kDa), Smac/DIABLO (23 kDa), and Omi/Htra2 (37 kDa)
but not AIF (56 kDa) are released from cancer cell mitochondria.
doi:10.1371/journal.pone.0009924.g003
Figure4.ABT-737induces aBax/Bak-dependentcytochromecrelease.A.Totalcellextracts fromHCT-116Bax+/-,Bax-/-,Bak-/-andBax/Bak-/-
(DKO) cell lines were subjected to Bax and Bak immunoblot to control their Bax and Bak content. B. Mitochondria isolated from HCT-116 Bax +/-, Bax -/-,
Bak -/- and Bax/Bak -/- (DKO) cell lines were incubated with increasing concentrations of ABT-737 and the supernatant was subjected to immunoblot
detection of cytochrome c (NT: untreated; Ala: alamethicin 20 mg/ml). C. Cytochrome c release induced by t-Bid and ABT-737 is inhibited by an excess of
recombinant Bcl-xL. PC-3 mitochondria were incubated with ABT-737 (1 mM) or t-Bid (1 nM) for 45 min after a 5 min-pretreatment with recombinant Bcl-
xL (100 to 400 nM) and the supernatant was subjected to anti-cytochrome c immunoblot (NT: untreated; Ala: alamethicin 20 mg/ml). Note that Bcl-xL
strongly reduces both t-Bid and ABT-737-induced cytochrome c release (n=2 independent experiments).
doi:10.1371/journal.pone.0009924.g004
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PLoS ONE | www.plosone.org 6 March 2010 | Volume 5 | Issue 3 | e9924Figure 5. ABT-737 induces Bax and/or Bak oligomerization. Mitochondria isolated from PC-3 (A) and Jurkat (B) cell lines were incubated or
not with the BCB, a Bax Channel Blocker (2 mM( 6)-1-(3,6-dibromocarbazol-9-yl)-3-piperazin-1-yl-propan-2-ol) prior to treatment with 1 mM Bim BH3,
10 mM Bak BH3, 10 mM mutated Bak BH3, 1 nM t-Bid or indicated concentrations of ABT-737. Supernatants were analyzed for cytochrome c release
(lower panels; NT: untreated; Ala: alamethicin 20 mg/ml) and mitochondrial pellets were treated with the irreversible crosslinker BMH (1 mM). Forty
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PLoS ONE | www.plosone.org 7 March 2010 | Volume 5 | Issue 3 | e9924The recombinant t-Bid protein, Bak BH3, Bim BH3 and ABT-
737 triggered a release of apoptogenic proteins from PC-3 and
Jurkat mitochondria by formation of channels large enough to
release proteins such as Omi/HtrA2 (37 kDa) (Fig. 3). OMP
appears independent on PTP since it is not inhibited by known
PTP inhibitors like ADP, cyclosporin A and bongkrekic acid (not
shown). The absence of mitochondrial membrane alterations (no
swelling and DYm loss) (Fig. 2A) and the release of the smallest
apoptotic factors under treatment (Fig. 3) suggested that ABT-737
induced the formation of a specific channel and not a
mitochondrial membrane rupture, similarly to the Bax[53–86]
BH3 peptide in Polster et al. [36]. Accordingly, discriminative
Figure 6. Pro- and anti-apoptotic protein pattern of isolated mitochondria. Total cell extracts (TE) and mitochondrial extracts (M) from PC-3,
HT-29, Jurkat and HCT-116 cancer cell lines or from healthy HME-1 cell line and mouse liver were analyzed by Western blot for detection of the anti-
apoptotic (A) Bcl-2, Bcl-xL, Bcl-w, Mcl-1L and A1 proteins and the pro-apoptotic (B) Bak, Bax, Bim, Bad and Mcl-1S proteins.
doi:10.1371/journal.pone.0009924.g006
micrograms protein from each reaction was run on SDS-PAGE and immunoblotted with anti-Bax (A) or anti-Bak (A, B) antibodies. Bax/Bak
oligomerization accompanies ABT-737-induced cytochrome c release which is inhibited by BCB.
doi:10.1371/journal.pone.0009924.g005
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HeLa mitochondria treated with t-Bid [37]. This finding is
compatible with the previous description of an apoptosome-
dependent loop where downstream caspases need to be activated
to trigger mitochondrial release of AIF and EndoG, secondary to
the release of cytochrome c, Omi/HtrA2 and Smac/DIABLO
[37]. In cellular model, DYm loss and cytochrome c release were
simultaneously detected in response to ABT-737 [38,39] contrary
to what was observed with our conditions in cell-free system. Our
screening method seems to be a real time process that allows
detection of direct and early effects of compounds on mitochon-
dria, without interferences induced by cytosolic compartment.
We have also shown that (1) HCT-116 Bak-/-, but not Bax-/-,
mitochondria are sensitive to ABT-737 (Fig. 4A), (2) ABT-737-
induced cytochrome c release on PC-3 mitochondria are
controlled by an excess of Bcl-xL (Fig. 4C) and (3) inhibition of
Bax and Bak oligomerization by BCB is sufficient to block
cytochrome c release (Fig. 5A and B). These findings indicate that
equilibrium between pro-apoptotic and anti-apoptotic members of
the Bcl-2 family plays an essential role in the ABT-737 mechanism
of action.
We have thus demonstrated that Bax and Bak oligomerization
at the PC-3 mitochondrial membrane is induced by Bak and Bim
BH3 peptides, t-Bid or ABT-737 treatments (Fig. 5A), Bax and
Bak both being inserted as a monomeric form in untreated normal
(HME-1) and tumoral (PC-3) cell mitochondria. However,
numerous studies have been performed showing Bax oligomeri-
zation and subsequent membrane insertion using recombinant
Bax and isolated mitochondria or liposomes [40–42]. These
studies have led to opposite conclusions on the kinetic of Bax pores
activation. However, more recently, it has been shown that
oligomerization of Bax occurs at the mitochondrial level rather
than in the cytosol [43–45]. Thus, using c-myc null cells, Annis
and co-workers showed that Bax-induced mitochondrial permea-
bilization results from oligomerization of transmembrane mono-
mers rather than insertion as preformed oligomers [43].
Some Bcl-2 family proteins, such as the BH3 only activator Bim
or the anti-apoptotic proteins Bcl-2 and Mcl-1L are especially
present at cancer cell mitochondria. In contrast with previous
observations [28,29,46], Mcl-1L expression at the mitochondria
was not sufficient in our hands to prevent MOMP formation in
response to ABT-737. For instance, PC-3 and Jurkat mitochondria
are sensitive to low concentrations of ABT-737 despite a high Mcl-
1L content (Figs 2 and 6), while HT-29 mitochondria with low
level of Mcl-1L are relatively resistant to ABT-737. We show here
that at the molecular level, ABT-737 allows pro-apoptotic proteins
Bcl-2 and Bcl-xL but neither Mcl-1L nor Bcl-w to liberate Bax,
Bak and Bim (Figs 7 and 8). Bim, as activator of Bax and Bak
oligomers, plays a key role in ABT-737-induced apoptosis [47].
This suggests that sensitivity to ABT-737 depends on Bim presence
and on the balance between the quantity of Bcl-2 and Bcl-xL versus
Mcl-1L and Bcl-w, explaining resistance of some mitochondrial
types, deprived of Bcl-2 (HT-29 mitochondria) or both Bcl-2 and
Bim (HME-1 and liver mitochondria). Interestingly, HME-1
mitochondria are less sensitive to t-Bid than cancer cell
mitochondria despite the presence of Bax and Bak (Fig. 6). This
observation suggests a slight difference in Bax and Bak regulation
in healthy and cancer mitochondria isolated from cultured cell
lines. Extended investigations are needed to explain this difference.
Finally, the comparative approach based on isolated ‘‘patho-
logical’’ versus ‘‘healthy’’ mitochondria appears to be a usefull tool
to identify Bcl-2 inhibitors and investigate their mechanism of
action on a particular cell type. It also represents a reliable, fast,
and predictive screening tool, tailored for selecting series or
compounds with selective toxicity profile against mitochondria
from cancer cell lines and devoid of toxicity against healthy
mitochondria.
Materials and Methods
Peptides and reagents
The human Bak BH3 (CMGQVGRQLAIIGDDINRRYDS),
mutated [L78A; D83A] Bak BH3 and Bim BH3 (CEIWIAQELR-
RIGDEFNAYYAR) peptides were purchased at Abgent (Interchim
SA, Montluc ¸on, France). The low molecular weight mitochondrio-
toxic compounds used are: HA-14.1, YC-137, Chelerythrine, EM20-
25 and Gossypol (Sigma-Aldrich, St Quentin Fallavier, France);
recombinant t-Bid (gift from Dr. J.C. Martinou); TW-37 and ABT-
737 (synthetized by Almac Sciences, UK). Other compounds used
are: Bax channel blocker (BCB; (6)-1-(3,6-dibromocarbazol-9-yl)-3-
piperazin-1-yl-propan-2-ol; Calbiochem, San Diego, CA); cyclospor-
in A (CsA; BIOMOL Research Laboratories, Inc, Tebu Bio SA, Le
Perray en Yvelines, France); oligomycin and mClCCP (m-chlor-
ocarbonylcyanide phenylhydrazone, Sigma Aldrich) and the recom-
binant protein Bcl-xL (Oncogene
TM Research products, Merck,
VWR international, Fontenay sous bois, France).
Purification of mice liver and tumor cell lines
mitochondria
Liver mitochondria were isolated from 6 weeks old BALB/cByf
female mice (Charles River, Saint Germain sur L’arbresle, France) as
previously described [30]. Animal housing, care and application of
experimental procedures were conducted in compliance with the
European Community guidelines for the care and use of experimen-
tal animals (Animal Health Regulations, Council Directive No. 86/
609/EEC of 24
th November 1986). The experimental procedure on
mice was rewieved and approved by the Bichat - Debre ´H o s p i t a l s
Ethics Committee. Purified organelles were re-suspended in homo-
geneization buffer (300 mM sucrose, 5 mM TES pH 7.2, 0.2 mM
EGTA, 1 mg/ml BSA). Mitochondria were also isolated from
human mammary gland epithelial cells immortalized by stable
expression of the human telomerase reverse transcriptase [48]
(hTERT-HME-1; ATCC) and human cancer cell lines (PC-3,
prostate adenocarcinoma (NCI); HT-29, colon adenocarcinoma
(ATCC); Jurkat, acute T cell leukemia (ATCC); HCT-116, colon
adenocarcinoma, deficient or not for Bax and/or Bak (from Dr. Peter
Daniel and Prof. Bert Vogelstein). Briefly, adherent cells were
harvested with Trypsin/EDTA, centrifuged at 750 rpm for 10 min,
washedinbufferA(100 mMsucrose,1 mMEGTA,20 mMMOPS,
pH 7.4 and 1 mg/ml BSA) before cell break with a Dounce
homogenizer. The suspension was centrifuged twice at 2 500 g for
5m i na n dt h er e s u l t i n gs u p e r n a t a n ta t1 00 0 0gf o r1 0m i na t4 uC.
Figure 7. ABT-737 induces Bax and Bak liberation from Bcl-2 and Bcl-xL. Mitochondria isolated from PC-3 (A), HT-29 (B) and Jurkat (C) cells
were untreated (NT) or treated with t-Bid (Bid; 2 nM) or ABT-737 (ABT; 1 mM) before to be immunoprecipitated by the antibodies directed against the
Bcl-2, Bcl-xL and Mcl-1 anti-apoptotic proteins. Mitochondrial total extracts (TE; positive control of immunoblot; 25 mg) were used as control while a
mitochondrial lysate was subjected to immunoprecipitation process without antibody (C; negative control of immunoprecipitation). Thus Western
blot analysis was performed to determine bindings between anti-apoptotic proteins and pro-apoptotic Bax and Bak proteins (representative Western
Blots of 3 independent experiments).
doi:10.1371/journal.pone.0009924.g007
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EGTA, 20 mM MOPS pH 7.4, 1 mg/ml BSA and 1 mM PMSF)
and the homogenate was layered on a two phase percoll density
gradient. After centrifugation, mitochondria (layered at the interface)
were removed, washed with homogeneization buffer for 10 min. at
10 000 g, and resuspended in homogeneization buffer. To ensure
quality of mitochondrial preparations, samples were subjected to
various assays for integrity and functionnality including cytochrome
oxydase accessibility, respirometry and FSC/SSC FACScan (BD
Bioscience, Germany) analysis in the presence or absence of
Mitotracker
TM green (DYm insensitive) and Mitotracker
TM red
(DYm sensitive) as described in [30].
Figure 8. MOMP formation in PC-3 mitochondria in response to ABT-737. A. Bax, Bak and Bim are sequestred by Bcl-2, Bcl-xL and Mcl-1 at
the outer mitochondrial membrane. B. In response to ABT-737, Bax, Bak and Bim proteins are liberated from Bcl-2 and Bcl-xL but not from Mcl-1L.
Thus Bim can directly enhance Bax and Bak oligomerization triggering MOMP formation (C) and release of pro-apoptotic proteins such as
cytochrome c in the cytosol.
doi:10.1371/journal.pone.0009924.g008
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Our screening platform is dedicated to the real-time co-
monitoring of mitochondrial swelling and DYm. Freshly isolated
mitochondria are distributed in 96-well plates in buffer D (200 mM
sucrose, 5 mM succinate, 10 mM MOPS pH 7.4, 1 mM H3PO4,
2 mM rotenone and 10 mM EGTA) supplemented with 1 mM
rhodamine 123 (Rh123; Molecular Probes
TM, Invitrogen, Cergy
Pontoise, France) followed by the additionof serial dilutions of small
compounds or synthetic peptides. Absorbance at 545 nm and
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are
recorded during 30 cycles of 1 min using a fluorescence multi-well
plate reader (Infinite, TecanH,M a ¨nnedorf, Switzerland). CaCl2
(50 mM) and mCICCP (20 mM) treatments were considered as the
100% baseline for the swelling and DYm loss, respectively. The
EC50 are the concentrations corresponding to 50% of maximal
swelling and 50% of maximal DYm loss at 30 min.
Determination of cytochrome c, Smac/DIABLO,
Omi/Htra2 and AIF release
Isolated mitochondria (20 mg proteins) were incubated with
20 mg/ml Alamethicin (Ala, positive control, 100% baseline for
ELISA), small molecules or synthetic compounds in buffer D for
30 or 45 min at 30uC. After a 7 min centrifugation at 10 000 g,
proteins contained in supernatant were analyzed for quantification
of cytochrome c release using ELISA kits from MBL (Cliniscience,
Montrouge, France) for liver mitochondria and from Biosources
(Invitrogen) for tumor cell lines mitochondria and/or runned on
NuPAGEH 4–12% Bis-Tris gels (Invitrogen) and transfered to
nitrocellulose using the iBlot
TM Dry Blotting System (Invitrogen).
Subsequently the membrane was blocked for 1 h with 5% low fat
milk in TBS-0.1% tween-20 (TBST) and incubated with anti-
cytochrome c mouse monoclonal IgG2b antibody (BD Bioscience
Pharmingen; 1/500); or anti-Smac/DIABLO (Calbiochem; 1/
3000), anti-Omi/HtrA2 (R&D Systems, Lille, France; 1/2000),
anti-AIF (Upstate Biotechnology, Millipore, Billerica, MA;1/1000)
rabbit polyclonal IgG antibodies. After 1 h-washes with TBST, the
membrane was treated with horseradish peroxidase-coupled anti-
mouse IgG (Promega, Charbonnie `re, France; 1/2500) or anti-
rabbit IgG (Amersham Biosciences, Piscataway, NJ; 1/3000) for
ECL detection (Amersham Biosciences).
BMH cross-linking
A 20 mM stock of 1,6-bismaleimidohexane (BMH; Pierce)
prepared in DMSO was added to treated mitochondria at a 1:20
dilution in buffer D. After 1 hour at 30uC, mitochondria were
centrifuged 10 min at 12 000 g and dissolved in 4x NuPAGE
sample buffer (Invitrogen) with DTT (dithiothreitol) before SDS-
PAGE electrophoresis.
Determination of mitochondrial membrane-associated
proteins
Proteins were analyzed by Western blot using: anti-Bcl-2 (C-2,
Santa Cruz Biotechnology, Tebu Bio; 1/500) mouse monoclonal
IgG1 antibody; anti-Bcl-w (31H4, Cell Signalling; 1/1000), anti-
Mcl-1 (Y37, Abcam; 1/1000), anti-A1 (BioVision, Cliniscience; 1/
400), anti-Bax (N20; Santa Cruz Biotechnology; 1/1000), anti-Bak
(Upstate Biotechnology; 1/1000), anti-Bcl-xL (Pharmingen BD
Bioscience; 1/1000), anti-Bim (Calbiochem; 1/1000) or anti-Bad
(Cell Signaling, Ozyme, Montigny le Bretonneux, France; 1/1000)
rabbit polyclonal IgG antibodies.
Immunoprecipitation experiments
Isolated mitochondria (600 mg) were incubated or not with t-Bid
(2 nM) or ABT-737 (1 mM) during 40 min at 30uC. After
centrifugation for 10 min at 10 000 g, mitochondria were lysed
by incubation at 4uC during 15 min in 1 ml of CHAPS buffer
(Hepes 50 mM, KCl 150 mM, EDTA 1 mM, EGTA 1 mM,
CHAPS 0.2%, NP40 0.05%, NaF 5 mM and PMSF 1 mM). After
centrifugation for 10 min at 10 000 g, supernatant was incubated
for 16 h at 4uC with protein G agarose (Pierce) and antibodies:
mouse anti-Bcl-2 (Santa Cruz clone C-2), anti-Mcl-1 (Santa Cruz
clone 22) or rabbit anti-Bcl-xL (Cell Signaling). The precipitate
was washed 4 times with CHAPS buffer and boiled 5 min in
loading buffer before immunoblot analysis.
Electron microscopy
Isolated mitochondria were fixed with 2% glutaraldehyde in 0.1
M Na-cacodylate buffer, pH 7.2 for 3 h at 4uC. After 2 washes
with 0.2 M sucrose in 0.1 M Na-cacodylate buffer, pH 7.2, the
specimens were then postfixed with 1% osmium tetroxide
containing 1.5% potassium cyanoferrate, dehydrated in gradual
ethanol (30–100%) and embedded in Epon. 70 nm thin sections
were collected onto 200 mesh cupper grids, counterstained with
uranyl acetate and lead citrate before examination with a Zeiss
EM 902 transmission electron microscope at 80 Kvolt (MIMA2,
Electron Microscopy Platform-GPL, Jouy-en-Josas). Micropho-
tographies were acquired using MegaView III CCD camera and
analysed with ITEM software (Eloı ¨se SARL, Roissy, France).
Polarographic studies
Isolated mitochondria were incubated in a magnetically stirred
1.5 ml cell with a Clark type oxygen electrode (Hansatech
Instruments Ltd, Norfolk, UK) thermostated at 37uC, in 500 ml
of a medium consisting of 0.3 M mannitol, 10 mM phosphate
buffer (pH 7.3), 10 mM KCl, 5 mM MgCl2 and 1 mg/ml BSA as
previously described [49]. ADP addition causes a sudden burst of
oxygen uptake when the ADP is converted into ATP characterized
by an actively respiring state (state 3) respiration followed by a
slower rate after all the ADP has been phosphorylated to form
ATP (state 4). The ratio [state 3 rate] / [state 4 rate] which is
called the respiratory control index (RCI) indicates the tightness of
the oxidative phosphorylation, thus referring to the respiratory
chain functionality and the quality of the mitochondrial prepara-
tion. The inhibitor Oligomycin A which blocks respiration in
coupled mitochondria and the uncoupling agent mClCCP were
added in the case of tumoral cell mitochondria.
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